Trial · NCT03041701
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Ph I: Dose Level 1 and 2 Dose Escalation | STARTED | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 7 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | STARTED | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 6 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | STARTED | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | COMPLETED | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 6 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | COMPLETED | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 5 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | COMPLETED | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | NOT COMPLETED | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 1 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | NOT COMPLETED | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 1 | |
| Ph I: Dose Level 1 and 2 Dose Escalation | NOT COMPLETED | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | STARTED | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | STARTED | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | STARTED | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 1 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | COMPLETED | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | COMPLETED | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | COMPLETED | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | NOT COMPLETED | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | NOT COMPLETED | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 0 | |
| Ph 2:Dose Level 1 Maximum Tolerated Dose | NOT COMPLETED | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03041701/flow